Corrections Policy
The corrections policy of Peptides Vietnam is simple: when a page is wrong, we fix it and say so. Many fixes start with a reader, and the rest come from our own checks of older pages.
How to report a mistake
Email hello@peptidesvietnam.com with the page address, the line that is wrong, and why. A link to a better source helps, but it is not required.
Any of these counts: a misread study, a wrong unit or sum, a price that has moved, a dead or wrong citation, a law that has changed, or a sentence that reads like advice for one person.
What happens next
1. Check
We go back to the source the claim cites, or find the primary source if the page cited coverage of it.
2. Fix
A wrong fact is replaced with the right one, not softened with a hedge. A claim no source supports is cut.
3. Date
The page date moves, so a reader can see the page changed. The sitemap date moves with it.
Mistakes in dose figures, unit math or safety lines go to the front of the queue, ahead of wording and price fixes. If the same mistake sits on more than one page, every copy is fixed, not just the one that was reported.
When a correction is stated on the page
Small fixes, such as a typo or a smoother sentence, only move the page date. When a fix changes what a reader would have concluded, such as a figure, a legal status or a safety line, the page also says what changed and when, in a short correction note.
We do not quietly delete a page to hide a mistake. When we remove a page, we point its address to the closest page that is still right, where one exists.
Recent fixes
A sample from the last few weeks, so you can see the kind of mistake we catch and how we handle it:
30 October 2026. The DSIP page linked a PubMed record for a different paper, under a title PubMed does not have. It now links the right paper, Schoenenberger’s 1984 review.
30 October 2026. Two pages said no human trial of AOD-9604 had ever been published. A 2013 paper reports the safety results of six randomized trials, so both pages now say that, and cite it.
24 October 2026. The cagrilintide page listed the dose groups from its phase 2 trial wrongly. They now match the paper (Lau and colleagues, The Lancet, 2021).
24 October 2026. Statements about the FDA’s compounding category 2 list were brought in line with the FDA’s own page as it read on 23 October.
Most of these were found by our own audits, not by readers. Older pages are re-checked in batches, and every new page gets a second, independent review before it goes live.
Reviewed pages
When a page carries a review line and a correction changes a health fact on it, the page goes back to its reviewer. The medical review policy explains what happens to the review line in the meantime.
The rules every page is written under are in the editorial policy. Other ways to reach us are on the contact page.
Disclaimer: All information on this site is for educational purposes only. Not medical advice.